Skip to main content

Industry News

  • (Business Wire India; 16th June, 2014); Acute myeloid leukaemia (AML) is a devastating form of blood cancer that mainly affects people over 60 years old. For older patients who receive chemotherapy, the median survival is less than a year. Even though AML is considered rare, it accounts for around 18,860 new cases and 10,000 deaths in the US each year and is the most frequent cause of leukaemia-related deaths.

  • (Business Wire India; 3rd June, 2014); Bristol-Myers Squibb and Syngene International, India’s largest contract research organization, today announced a five-year extension of their drug discovery and development collaboration in India. Financial terms were not disclosed.
    Since 2007, Bristol-Myers Squibb has been working with Syngene and its corporate parent, Biocon Ltd., to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development at the Biocon Bristol-Myers Squibb Research Center (BBRC) in Bangalore.

  • (Business Wire India; 19th May, 2014); Ferring Pharmaceuticals marks World IBD Day (May 19th) with the launch of Guts4life (guts4life.com), a new interactive website with information, support and inspiration for people concerned with Crohn’s disease and ulcerative colitis, conditions known as inflammatory bowel diseases (IBD). IBD describes a range of chronic diseases of the gastrointestinal system characterised by intermittent flares with debilitating symptoms that can affect a patient’s quality of life and lead to emotional distress and social isolation. Guts4life was designed together with IBD patients to provide support and encouragement throughout the IBD journey—from bowel symptom worries, to diagnosis, through managing and living with IBD.

    [adsense:336x280:8701650588]

  • Jubilant Biosys and Orion Corporation Announces Unique Collaborative Discovery Program in Pain Management Area

    (Business Wire India; 13th May, 2014); Jubilant Biosys, a Bengaluru-based subsidiary of Jubilant Life Sciences, and Orion Corporation (Orion), the largest pharmaceutical company in Finland, today announced a path breaking drug discovery collaboration to discover small molecule inhibitors in neuroscience therapeutic area. The research deal is aimed at developing drug that can benefit large population of people with unmet needs in the pain management area.

  • First time in India Continuing Pharmaceutical Education (CPE) to be held in Dombivli

    (12th May, 2014); InClinition, a Pharmaceutical and clinical research service providing organization situated in Dombivli, Dist. Thane has announced Continuing Pharmaceutical Education (CPE) discussion forum lecture series. This will be seminar cum networking session for industry and academic professionals.

  • ACG's Pithampur Factory Awarded Gold Rating by LEED-India; First in Pharma Industry to Receive the Certification

    (PRNewswire; 6th May, 2014); ACG's continued commitment towards sustainability and efforts in building sustainable sites, reducing water and energy consumption, recycling building material and improving indoor environmental quality has now been recognized. Indian Green Building Council (IGBC) LEED®-India has awarded its prestigious Gold rating to ACG's new state-of-the-art capsule manufacturing plant in Pithampur, making it the first factory in Indian pharmaceutical industry to receive this rating.

  • Boehringer Ingelheim to present highly anticipated Phase III data in IPF and COPD at ATS International Conference

    (30th Apr, 2014);Boehringer Ingelheim announced today that the first results of the two confirmatory Phase III INPULSISTM trials, investigating nintedanib* in the treatment of idiopathic pulmonary fibrosis (IPF), will be presented at the 2014 American Thoracic Society (ATS) International Conference taking place 16 – 21 May in San Diego. IPF is a rare, debilitating and fatal lung disease for which treatment options are limited.

  • Portfolio transformation between Pharma Giants - GlaxoSmithKline, Novartis & Lilly

    (24th Apr, 2014); Now Novartis will focus more on oncology business, GlaxoSmithKline will focus on vaccines business and Lilly to concentrate more on Animal Health Division, concluded from portfolio transformation deals between said companies.

  • Shiseido Opens Research Facility Dedicated to Hair Regeneration

    Shiseido Co., Ltd. announces plans to open the Shiseido Cell-Processing and Expansion Center (SPEC) on May 1, 2014. The center, located in the in the Kobe Biomedical Innovation Cluster in Kobe, Japan, will centralize research and development on hair regenerative medicine with an aim toward commercialization.

Subscribe to Industry News